Clinical Trial Update: G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing granulocyte colony-stimulating factor (G-CSF) and erythropoietin for survival in patients with decompensated liver disease has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Liver Disease
• Liver Cirrhosis

Drugs mentioned

• Erythropoietin (erythropoietin)
• Granulocyte Colony-Stimulating Factor (G-CSF) (G-CSF)

Snippet

Sponsor: Institute of Liver and Biliary Sciences, India | Conditions: Chronic Liver Disease | Phase 3 | Status: COMPLETED